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Cell Cycle, Cell Death, and Senescence
Protein Kinase Casein Kinase 2–Mediated Upregulation of
N-Cadherin Confers Anoikis Resistance on Esophageal
Carcinoma Cells
Hyeonseok Ko1, Seongrak Kim1,2, Cheng-Hao Jin1, Eunjung Lee1,2, Sunyoung Ham1,2, Jong In Yook3,4, and
Kunhong Kim1,2
Abstract
Previously, we reported that high PKCK2 activity could protect cancer cells from death receptor–mediated
apoptosis through phosphorylation of procaspase-2. Because anoikis is another form of apoptosis, we askedwhether
PKCK2 could similarly confer resistance to anoikis on cancer cells. Human esophageal squamous cancer cell lines
with high PKCK2 activity (HCE4 and HCE7) were anoikis-resistant, whereas cell lines with low PKCK2 activity
(TE2 and TE3) were anoikis-sensitive. Because the cells showed different sensitivity to anoikis, we compared the
expression of cell adhesionmolecules between anoikis-sensitive TE2 and anoikis-resistant HCE4 cells using cDNA
microarray. We found that E-cadherin is expressed only in TE2 cells; whereas N-cadherin is expressed instead of
E-cadherin inHCE4 cells. To examinewhether PKCK2 activity could determine the type of cadherin expressed, we
ﬁrst increased intracellular PKCK2 activity in TE2 cells by overexpressing the PKCK2a catalytic subunit using
lentivirus and found that high PKCK2 activity could switch cadherin expression from type E to N and confer
anoikis resistance. Conversely, a decrease in PKCK2 activity in HCE4 cells by knockdown of PKCK2a catalytic
subunit using shRNA induced N- to E-cadherin switching and the anoikis-resistant cells became sensitive. In
addition, N-cadherin expression correlated with PKB/Akt activation and increased invasiveness. We conclude that
high intracellular PKCK2 activity confers anoikis resistance on esophageal cancer cells by inducingE- toN-cadherin
switching. Mol Cancer Res; 10(8); 1032–8. 2012 AACR.
Introduction
Six essential alterations in cell physiology can result in
malignant growth of cancer cells. These are described as "the
hallmarks of cancer" (1) and include: (i) sustaining prolif-
erative signaling, (ii) evading growth suppressors, (iii) resist-
ing cell death, (iv) enabling replicative immortality, (v)
inducing angiogenesis, and (vi) activating invasion and
metastasis (1). Cancer cell invasion of surrounding tissues
and metastasis to distant organs is the primary cause of death
for most cancer patients. The sequential steps in the path-
ogenesis of cancer metastasis include vascularization, inva-
sion, detachment, embolization, survival in the circulation,
arrest, extravasation, evasion of host defense, and progressive
growth (2). Approximately one million circulating tumor
cells are shed per gram of tumor tissue (3, 4) but fewer than
0.1% of cancer cells are viable within 24 hours after entry
into the circulation and fewer than 0.01% survive to produce
metastases (5). The low success rate ofmetastasis could result
from the presence of physiologic barriers to metastasis such
as anoikis and tumor surveillance.
Anoikis is a type of apoptosis that is induced by loss of cell
adhesion to the extracellular matrix (ECM) and is an
intrinsic characteristic of normal epithelial cells (6). In
contrast to normal epithelial cells, cancer cells are resistant
to anoikis and adhesion to the ECM is not required for their
survival and proliferation. Accordingly, acquisition of anoi-
kis resistance might be a molecular prerequisite for the
successful metastatic spread of cancer cells. Cancer cells have
developed strategies to become resistant to anoikis, which
converge in the activation of survival signals (7). Such
strategies include a switch in integrin expression (8, 9),
reactive oxygen species–mediated Src oxidation/activation
(10, 11), epithelial mesenchymal transition (EMT; refs. 12–
14), constitutive activation of survival signaling components
such as Src, PKB/Akt, or ERK (15–17), or overexpression of
tropomyosin-related kinase B (TrkB; refs. 18 and 19).
PKCK2 is a constitutively active, growth factor–indepen-
dent serine/threonine protein kinase with key roles in cell-
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cycle control, cellular differentiation, proliferation, and
regulation of apoptosis (20–22). Changes in PKCK2 expres-
sion or activity have been reported in many cancer cells
(21, 23–25) and overexpression of PKCK2 catalytic subunit
can induce tumor formation (23). Inhibition of TNF-related
apoptosis inducing ligand (TRAIL) death receptor–mediat-
ed apoptosis by PKCK2 might be important in the metas-
tasis of cancer cells (21) because natural killer (NK) cells play
a physiological role in tumor surveillance by presenting
surface expressed TRAIL to incoming circulating cancer
cells to induce apoptosis (26). Incoming cancer cells with
high PKCK2 activity are resistant to TRAIL-mediated
apoptosis and cannot be removed from the circulation,
allowing their successful spread to distant sites (27). PKCK2
is also known as a positive regulator of the Wnt signaling
pathway that is important for metastasis of cancer cells (28).
Known PKCK2 substrates involved in Wnt signaling are
dishevelled, b-catenin, and Snail. Snail is known to repress
expression of the adhesion molecule E-cadherin (29, 30).
Phosphorylation at Thr 393 on b-catenin protects it from
proteosomal degradation, thereby increasing its nuclear
translocation and cotranscriptional activity (31, 32).
Increased expression of Axin2 by b-catenin results in trans-
portation of GSK3b out of the nucleus, thereby protecting
Snail from GSK3b-mediated degradation and inducing
E-cadherin downregulation (33). In addition, phosphory-
lation of Snail at Ser 92 by PKCK2 results in its stabilization
and thus downregulates E-cadherin expression (34).
Although PKCK2 acts as an antiapoptotic regulator in
death receptor–mediated apoptosis, little is known about its
association with anoikis of cancer cells. Accordingly, the
purpose of this study was to examine whether PKCK2
confers anoikis resistance on esophageal cancer cells.
Materials and Methods
Cell culture and reagents
The human esophageal cancer cell lines TE2, TE3,
HCE4, and HCE7 were grown as previously described
(35). To induce anoikis, cells were plated on poly-2-hydro-
xyethylmethacrylate-coated culture plates (poly-HEMA;
Sigma-Aldrich) as previously described (36).
cDNA microarray
The cDNA microarray assay was conducted using a
GEArrayTMQ series kit purchased from Superarray Bio-
science Co. and was used according to the manufacturer's
protocol.
Western blot analysis
Western blot analysis was carried out as previously
described (37). Cells were lysed in RIPA buffer (1 M Tris
[pH 8.0], 5MNaCl, 100mmol/L EGTA, 10%NP-40, and
0.25% sodium deoxycholic acid) with 1 complete protease
inhibitor cocktail (Roche Diagnostics). Lysates were brieﬂy
vortexed and cleared by centrifugation at 12,000 r.p.m. for
10 minutes at 4C. Supernatants were collected and protein
concentration determined by Bradford assay (Bio-Rad).
SDS-PAGE (10–12%) was conducted followed byWestern
blotting. The blotted membranes were immunostained with
antibodies speciﬁc for the following antigens: Akt, phospho-
Akt (Ser-473), PARP, cleaved caspase-3 (Cell Signaling
Technology Inc.); procaspase-3 (BD Pharmingen); E-cad-
herin, N-cadherin (Invitrogen Co.); keratin10, involucrin,
vimentin, a-tubulin (Santa Cruz Biotechnology Inc.);
PKCK2a (Upstate), and b-actin (Sigma-Aldrich Co.). The
signals were developed using a standard enhanced chemi-
luminescence method according to the manufacturer's pro-
tocol (Amersham Pharmacia Biotech Inc.).
Cell proliferation assay
Cells were plated on poly-HEMA-coated tissue culture
plates and proliferation rates were measured using a sulfor-
hodamine B colorimetric (SRB) assay. After collection of the
cells and removal of the medium by aspiration, cells were
ﬁxed in 50 mL ice-cold 10% trichloroacetic acid (TCA) and
incubated at 4C for 30 to 60 minutes. The cells were
washed 5 times with water and allowed to air dry for 5
minutes. Fifty microliters of 0.4% sulforhodamine B solu-
tion in 1% acetic acid was added and the cells were incubated
for 30 minutes at room temperature. The stained cells were
washed 4 times with 1% acetic acid and allowed to air dry for
5 minutes, solubilized in 100 mL of 10 mmol/L Tris (pH
10.5), and placed on an orbital rotator for 5 minutes.
Supernatants were collected and absorbance at 570 nm was
read using an UV-spectrophotometer.
RNA interference, lentiviral expression, and generation
of stable cell lines
siRNA was purchased from Dharmacon, Inc. (Option
A4). The target sequence for N-cadherin was CAUAUGU-
GAUGACCGUAAC (nucleotides 851–869). Cells were
transfected with siRNA using Lipofectamine 2000 (Invitro-
gen Life Technology) according to the manufacturer's pro-
tocols. For overexpression of PKCK2a, the lentivirus vector
Lentipgk-GFP mCMV-HA-PKCK2a IRESpuro was pur-
chased from Macrogen and cotransfected into 293FT cells
with packaging plasmids. The resulting supernatant contain-
ing PKCK2a-expressing lentivirus was used to transduce
cells according to the manufacturer's protocol (Macrogen).
Transduced cells were selected using puromycin (1 mg/mL).
A human shRNA kit for silencing PKCK2a expression was
purchased from Origene Technologies Inc. To obtain stable
transfectants, cells were transfected with the plasmid and
then treated with puromycin (2 mg/mL) for selection.
In vitro PKCK2 kinase activity assay
Intracellular PKCK2 activity was measured using an in
vitro kinase assay as previously described with slight mod-
iﬁcation (25). Brieﬂy, 3 mg of bacterially expressed GST-CS
(CK2 substrate) protein was incubated with glutathione
Sepharose 4B beads for 60 minutes and washed twice with
1 kinase buffer (4 mmol/L MOPS, pH 7.2, 5 mmol/L
b-glycerolphosphate, 1 mmol/L EGTA, 200 mmol/L sodi-
um orthovanadate, and 200 mmol/L DTT). The beads were
then incubated with 100 mg cell lysate in a ﬁnal volume of
PKCK2 Confers Anoikis Resistance
www.aacrjournals.org Mol Cancer Res; 10(8) August 2012 1033
on August 14, 2013. © 2012 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Published OnlineFirst July 5, 2012; DOI: 10.1158/1541-7786.MCR-12-0261 
50 mL kinase reaction buffer (10 mL of 5 kinase buffer), 10
mLmagnesium/ATP cocktail solution [90 mL of 75 mmol/L
MgCl2/500 mmol/L ATP plus 10 mL (100 mCi) [g-32P]-
ATP] for 20 minutes at 30C. Reactions were stopped by
washing twice with 1 kinase buffer. Samples were resus-
pended with 30 mL of 2 SDS sample loading buffer,
subjected to 12% SDS-PAGE followed by staining with
Coomassie brilliant blue, and dried on Whatman papers.
Incorporation of 32P was detected by autoradiography.
Cell invasion assay
The cell invasion assay was conducted using a Cell
Invasion Assay Kit purchased from CHEMICON Interna-
tional, Inc.
Results
Endogenous PKCK2 activity and anoikis
To examine whether intracellular PKCK2 activity is a
determinant of anoikis resistance, esophageal cancer cell lines
that show high (HCE4 and HCE7) or low (TE2 and TE3)
PKCK2 activity (21) were cultured on poly-HEMA coated
tissue culture plates. A cell viability assay showed that the
number of HCE4 or HCE7 cells was increased 7.5- and 5-
fold respectively, at 48 hours after suspension, whereas the
number of TE2 or TE3 cells decreased 0.5-fold under the
same conditions (Fig. 1A). Unlike anoikis-sensitive TE2
cells, anoikis-resistant HCE4 cells formed large, spheroid
aggregates in suspension (Fig. 1B). Western blot analysis
showed that TE2 cells began to undergo apoptosis after 24
hours in suspension but HCE4 cells did not, even after 48
hours of suspension (Fig. 1C). These results suggest that
PKCK2 activity might be a determinant of anoikis
resistance.
Cadherin expression and anoikis
Because the cancer cells responded differently to detach-
ment, we compared the expression level of adhesion mole-
cules between anoikis-sensitive TE2 and anoikis-resistant
HCE4 cells using the GEArrayTM Q series Human Extra-
cellular Matrix & Adhesion Molecules Gene Array, which
contains 96 genes encoding proteins important for the
attachment of cells to their surroundings. E-cadherin expres-
sionwas observed only inTE2 cells (data not shown) and this
differential cadherin expression was conﬁrmed by Western
blot analysis (Fig. 2A and Supplementary Fig. S1). Although
HCE4 cells express keratin 10 and involucrin, markers of
terminal differentiation of epithelial cells, they also express
vimentin, a marker for mesenchymal cells, and N-cadherin
instead of E-cadherin, suggesting that the cells might be able
to transit from epithelial to mesenchymal cells (Fig. 2A). To
examine whether the expression of N-cadherin is required
for survival of cancer cells in suspension, N-cadherin
expression in HCE4 cells was silenced using siRNA.
Although HCE4 cells that expressed N-cadherin were
resistant to anoikis, N-cadherin-silenced HCE4 cells under-
went anoikis (Fig. 2B). These data indicate that N-cadherin
expression is necessary for cancer cells to become resistant to
anoikis.
PKCK2 activity and cadherin switching
To examine whether there is a causal relationship between
intracellular PKCK2 activity and the type of cadherin
expressed in the cell, the PKCK2a catalytic subunit was
either overexpressed in TE2 cells using lentivirus or
knocked-down in HCE4 cells using shRNA to increase or
decrease intracellular PKCK2 activity, respectively. Over-
expression of PKCK2a catalytic subunit in TE2 cells
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Figure 1. PKCK2 activity and anoikis. A, TE2, TE3, HCE4, or HCE7 cells were cultured on the poly-HEMA-coated tissue culture plates for the indicated times
and tested for viability with the SRB assay. The data are expressed as mean  SD for triplicates. B, TE2 and HCE4 cells were plated on poly-HEMA-coated
tissue culture plate (Poly-HEMAþ) and photographed using phase contrast microscopy 16 hours after plating. C, Western blot analysis was conducted to
conﬁrm apoptosis using cell lysates for the indicated time points.
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resulted in a marked increase in PKCK2 activity, epithelial–
mesenchymal transition as evidenced by E-to N-cadherin
switching, and the induction of vimentin expression (Fig.
3A). As expected, TE2-GFP cells underwent anoikis whereas
TE2-CK2a cells were resistant to anoikis (Fig. 3B). When
N-cadherin expression was knocked-down in TE2-CK2a
cells using siRNA against N-cadherin, the cells reverted to
anoikis sensitivity (Fig. 3C).
Conversely, knockdown of the PKCK2a subunit in
HCE4 cells (HCE4 CKD) resulted in a decrease in PKCK2
activity, mesenchymal–epithelial transition as evidenced by
N-to E-cadherin switching, and reduction of vimentin
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downregulation, PKB/Akt inactivation, and anoikis. HCE4 cells were transfectedwith either a scrambled siRNA (Sc) or N-cadherin siRNA (N) for 48 hours. The
cells were then cultured on poly-HEMA-coated plates for 48 hours. Cell viability assay (left) and Western blot analysis (right) were carried out. The data are
expressed as mean  SD for triplicates.
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Western blot analysis and in vitro kinase assay for intracellular PKCK2 activity were conducted. 32P-GST-CS (GST-tagged recombinant CK2 Substrate)
represents phosphorylated GST-CS and GST-CS represents Coomassie blue stained input GST-CS. B, TE2-GFP and TE2-CK2a cells were cultured
on poly-HEMA-coated plates for 48 hours.Western blot analysis (top) and cell viability assay (bottom) were conducted. The data are expressed asmeanSD
for triplicates. C, TE2-CK2a cells were transfected with either a scrambled siRNA (Sc) or N-cadherin siRNA (N) for 48 hours. The cells were then
cultured on poly-HEMA-coated plates for 48 hours. Western blot analysis (top) and cell viability assay (bottom) were conducted. The data are expressed as
mean  SD for triplicates.
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expression (Fig. 4A). The expression pattern of mRNA for
each gene (E-cadherin, N-cadherin, vimentin, and
PKCK2a) was the same as that of protein (data not shown).
Control HCE4 cells (HCE4 VC) were resistant to anoikis
whereas HCE4 CKD cells became apoptotic after 48 hours
of suspension (Fig. 4B). Taken together, these results indi-
cate that PCKC2 activity determines the type of cadherin
expressed on the cells.
N-cadherin–mediated PKB/Akt activation
Because PKB/Akt is a well-known survival signal, we
measured PKB/Akt activity in these cells by Western blot
analysis of Akt ser-473 phosphorylation (36, 37) and found
that PKB/Akt was active in N-cadherin-expressing HCE4,
HCE7 cells (Fig. 2A and Supplementary Fig. S1B) and TE2-
CK2a cells (Fig. 3B, top) that are resistant to anoikis. When
N-cadherin expression was knocked-down using siRNA in
HCE4 (Fig. 2B) or TE2-CK2a cells (Fig. 3C), PKB/Akt
activity was decreased and the cells became apoptotic in
suspension. These results indicate that PKCK2-dependent
upregulation ofN-cadherin could activate PKB/Akt, thereby
conferring anoikis resistance on cancer cells.
Increased invasiveness by N-cadherin
It has been known that N-cadherin-expressing cancer cells
are more invasive and metastatic than E-cadherin-expressing
cells (38–40). Thus, we examined invasiveness using a cell
invasion assay kit and found that N-cadherin-expressing
HCE4, HCE7, and TE2-CK2a cells were more invasive
than E-cadherin-expressing TE2, TE3, and TE2-GFP cells
(Fig. 5A and B). In addition, N-cadherin-silenced HCE4
cells (N) were less invasive than N-cadherin-expressing
HCE4 cells (Sc, Fig. 5C). These results indicate that cancer
cells that have high intracellular PKCK2 activity become
more invasive probably because of N-cadherin upregulation.
Discussion
This study shows that intracellular high PKCK2
activity confers anoikis resistance on esophageal cancer
cells. We found that high intracellular PKCK2 activity
could induce E- to N-cadherin switching (Fig. 3A).
Upregulation of N-cadherin could activate PKB/Akt,
thereby making cancer cells resistant to anoikis (Figs.
2 and 3B, Supplementary Fig. S1B) as previously re-
ported in human melanoma and prostate carcinoma cells
(41, 42).
To induce E- to N-cadherin switching, PKCK2must play
dual roles. The ﬁrst is downregulation of E-cadherin expres-
sion. Snail is a well-known transcriptional repressor of E-
cadherin gene expression (29, 30), and PKCK2 might
stabilize Snail protein both directly and indirectly, thereby
resulting in downregulation of E-cadherin.Direct phosphor-
ylation on Snail at serine 92 could induce stabilization of
Snail protein (34 and Supplementary Fig. S2). Phosphory-
lation on b-catenin at threonine 393 (31, 32) also could
stabilize Snail protein indirectly through nuclear b-catenin–
mediated upregulation of Axin2 expression, Axin2-mediated
GSK3b shuttling out from nucleus, and inhibition of
GSK3b-mediated Snail degradation (33 and Supplementary
Fig. S3).
The second role of PKCK2 in E- to N-cadherin switching
is upregulation of N-cadherin gene expression. Unlike E-
cadherin gene regulation, little is known about PKCK2-
dependent regulation of N-cadherin expression. PKCK2
phosphorylates many target proteins to regulate their func-
tion (43–45) and/or the expression of genes downstream
(33, 45). Thus, it is possible that Myeloid Zinc Finger-1
(MZF1), a known transcriptional factor required for
N-cadherin gene expression (46) could be a substrate of
PKCK2 and may thus become stabilized and upregulate N-
cadherin expression.
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In summary, we have shown that high intracellular PKCK2
activity confers anoikis resistance on cancer cells by inducing
E- to N-cadherin switching. These ﬁndings suggest that
PKCK2 may play important roles in cancer metastasis,
becausePKCK2could induceEMT,confer anoikis resistance,
and/or enhance NK cell tumor surveillance.
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